163.68MMarket Cap-2913P/E (TTM)
5.570High4.190Low2.31MVolume4.190Open4.135Pre Close11.64MTurnover10.49%Turnover RatioLossP/E (Static)32.48MShares14.30052wk High-10.72P/B111.16MFloat Cap0.77052wk Low--Dividend TTM22.05MShs Float14.780Historical High--Div YieldTTM33.37%Amplitude0.660Historical Low5.034Avg Price1Lot Size
Candel Therapeutics Stock Forum
5.30+
Now Let's Get That 10.+ Back!
Let's Get 5.+
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Candel Therapeutics announced preclinical results for CAN-3110 in melanoma models, showing potential expansion beyond high-grade glioma treatment. CAN-3110, a first-in-class HSV-1 oncolytic viral immunotherapy, demonstrated potent antitumor activity in both in vitro human cel...
No comment yet